FRIDAY, Dec. 15, 2023 (HealthDay News) — In a recent trial, a new melanoma vaccine, mRNA-4157 (V940), when taken in combination with Keytruda (pembrolizumab), was found to be effective in battling the deadly skin cancer.
Clinical Trials
OBX-115 Elicits Responses in Advanced or Metastatic Melanoma
The tumor-infiltrating lymphocyte (TIL) cell therapy OBX-115 produced responses with no dose-limiting toxicities (DLTs) in heavily pretreated patients with advanced or metastatic melanoma whose who had progressed on anti–PD-1 and anti–CTLA-4 therapy with disease that was primary-resistant to immune checkpoint inhibitor (ICI) therapy, according to topline data from a phase 1 trial (NCT05470283).
BMS’ LAG-3 RELATIVITY theory fails futility test
Bristol-Myers Squibb has abandoned a bid to extend the indications of its combination of PD-1 inhibitor Opdivo and LAG-3 inhibitor relatlimab into colorectal cancer after it failed the phase 3 RELATIVITY-123 trial.
mRNA-4157 Plus Pembrolizumab Continues to Improve RFS in High-Risk Melanoma
Findings from 3-year follow-up of KEYNOTE-942/mRNA-4157-P201 show that the cancer vaccine mRNA-4157 plus pembrolizumab reduced the risk of recurrence or death in patients with stage III/IV melanoma following resection.